The Ross Levine Lab
Research
The goal of our research is to improve our understanding of the genetic basis of blood disorders known as myeloid malignancies, and to use this knowledge to improve therapies for patients with these disorders. Our efforts are focused on the identification and characterization of somatic mutations in hematologic malignancies using candidate gene, genome-wide, and functional approaches, with a specific interest in the role of aberrant signal transduction in malignant transformation and in the effects of mutations in epigenetic modifiers in myeloproliferative neoplasms (MPNs) and acute myeloid leukemia (AML). As a physician-scientist, we have a specific interest in translating this knowledge back to the clinic, in the preclinical and clinical evaluation of targeted therapies for leukemia patients, and in the development of clinically tractable genomic assays for patients with hematologic malignancies.
Featured News
People
Ross L. Levine, MD
Chief Scientific Officer; Senior Vice President, Memorial Hospital, Translational Research
- Mechanisms of genetic and epigenetic cooperativity which drive myeloid transformation; Elucidating and modeling evolution from hematopoietic stem/progenitor cells to clonal hematopoiesis and then to myeloid malignancies; Identification and credentialing novel therapeutic dependencies in myeloid malignancies
- MD, Johns Hopkins School of Medicine
- leviner@mskcc.org
- Email Address
- View physician profile
- Physician profile
Members
Achievements
- Scholar, Leukemia and Lymphoma Society Scholar (2012)
- Louis and Allston Boyer Young Investigator Award for Basic Research, Memorial Sloan Kettering Cancer Center (2011)
- Member, American Society of Clinical Investigation (2011)
- Sir William Osler Young Investigator Award, Interurban Clinical Club (2011)